Multiple Tumor Types - VMO-01C: Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymph

This is a multicenter, open-label, Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists

Location: Hartford Hospital

Contact: Hayley Dunnack, Hayley.Dunnack@hhchealth.org

Click here to view the clinicaltrials.gov listing for this trial.